Something has shifted in how mainstream medicine thinks about aging. For most of the twentieth century, aging was treated as an inevitable backdrop ā the silent cause behind every age-related disease, but not itself a target for intervention. The ambition of medicine was to treat cancer, heart disease, and dementia individually, not to address the biological processes that make all of them more likely in the first place.
That consensus is crumbling. In 2026, aging is increasingly viewed as a modifiable process ā one with identifiable molecular drivers, measurable biomarkers, and a growing set of interventions that appear to slow, halt, or in some cases partially reverse it. The longevity field has attracted billions in venture capital, produced a wave of serious clinical trials, and moved from the fringes of biohacker culture into respected academic medicine.
The signal-to-noise ratio, however, remains frustratingly low. For every genuinely promising intervention, there are a dozen supplements marketed with longevity language and backed by thin or non-existent human evidence. Separating the two requires navigating a rapidly evolving literature, conflicting incentives, and the fundamental challenge that running a 40-year human lifespan trial is impossible.
This article is an honest attempt to map the current evidence ā what looks genuinely promising, what remains uncertain, and what the strongest foundations for a long and healthy life still are.
The Hallmarks Framework: Why It Matters
Modern longevity research is anchored to a conceptual framework first published in 2013 and significantly updated in 2022: the hallmarks of aging. These are the cellular and molecular processes that accumulate over time and collectively produce the functional decline we associate with aging:
- Genomic instability ā accumulating DNA damage from radiation, reactive oxygen species, and replication errors
- Telomere attrition ā progressive shortening of protective chromosome caps
- Epigenetic alterations ā changes to gene expression patterns without changes to DNA sequence
- Loss of proteostasis ā declining capacity to clear misfolded and damaged proteins
- Deregulated nutrient sensing ā dysfunction in pathways that regulate cellular response to nutrient availability (mTOR, AMPK, sirtuins, IGF-1)
- Mitochondrial dysfunction ā declining energy production and increasing oxidative stress
- Cellular senescence ā accumulation of dysfunctional cells that refuse to die and secrete inflammatory signals
- Stem cell exhaustion ā declining regenerative capacity across tissues
- Altered intercellular communication ā including chronic low-grade inflammation (inflammaging)
- Disabled macroautophagy ā declining cellular recycling capacity
- Dysbiosis ā changes in the gut microbiome composition and function
- Altered mechanical properties ā changes in extracellular matrix and tissue stiffness
This framework matters because it gives researchers specific targets. Rather than asking the vague question "what makes people live longer?", they can ask more precise questions: which compounds reduce senescent cell burden, which activate autophagy, which preserve mitochondrial function?
What the Current Evidence Actually Supports
NAD+ Precursors: NMN and NR
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular energy metabolism, DNA repair, and the function of sirtuins ā a class of proteins involved in regulating cellular stress responses. NAD+ levels decline significantly with age, roughly halving between young adulthood and midlife, and this decline is implicated in mitochondrial dysfunction and impaired DNA repair.
Two precursors ā NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) ā can raise NAD+ levels in human tissue, and both have been extensively studied in animal models with impressive results. The human evidence is more modest but accumulating.
A landmark 2023 trial from Washington University found that NMN supplementation (250ā500 mg/day) in postmenopausal women improved muscle insulin sensitivity and skeletal muscle physiology. Several follow-on trials have replicated NAD+ elevation in blood and muscle tissue. A 2025 multi-site trial showed improvements in cardiovascular metrics and cognitive processing speed in adults over 60 taking NR at 1,000 mg/day over 24 weeks.
What we do not yet have is a long-term randomised controlled trial showing that NAD+ precursors meaningfully extend healthspan or reduce mortality in humans. The mechanistic rationale is strong; the clinical proof of concept is promising but incomplete.
Practical stance: NMN and NR appear safe at studied doses and show biological activity. They are among the most evidence-supported supplements in the longevity stack, with the caveat that "evidence-supported" does not yet mean "proven to extend human lifespan."
Rapamycin: The Boldest Bet
Rapamycin (sirolimus) is, by the measure of animal evidence, the most compelling longevity drug known. It inhibits mTORC1 ā a central nutrient-sensing pathway that, when chronically activated, drives cellular growth at the expense of maintenance and repair. In mouse studies, rapamycin extended median lifespan by 10ā15% even when started in midlife, and has been replicated across multiple independent laboratories.
Rapamycin is an FDA-approved immunosuppressant used in transplant medicine, which means there is extensive human safety data ā at daily doses used to prevent organ rejection. The longevity application involves low-dose intermittent dosing (typically 5ā10 mg once weekly), a protocol developed by clinicians like Dr. Matt Kaeberlein at the University of Washington to capture mTOR inhibition benefits while minimising immunosuppressive side effects.
The evidence base for this specific dosing protocol in healthy adults is still largely observational and retrospective ā drawn from physician surveys, patient reports, and small cohort studies. The PEARL trial, a randomised controlled trial of low-dose rapamycin in healthy older adults, is ongoing and expected to report in 2027.
Anecdotally, a significant and growing number of longevity-focused physicians are taking rapamycin themselves and prescribing it to patients outside clinical trials. Their self-reports are generally positive, with improved energy, immune function markers, and skin quality, but this evidence level is obviously limited.
Practical stance: The most intellectually honest position is that low-dose rapamycin is the most promising pharmacological longevity intervention in the pipeline, backed by stronger animal data than any other compound, but not yet proven in rigorous human trials at longevity doses. It is a prescription drug with genuine risks and should only be considered under medical supervision.
Senolytics: Clearing the Cellular Wreckage
Senescent cells are cells that have permanently stopped dividing but resist dying. In small numbers in youth, they serve important wound-healing and tumour-suppression functions. In larger numbers as they accumulate with age, they secrete a toxic cocktail of inflammatory molecules (the SASP ā senescence-associated secretory phenotype) that damages surrounding tissue and drives systemic inflammation.
Senolytics are compounds that selectively clear senescent cells. The most studied combination is dasatinib + quercetin (D+Q), where dasatinib is an FDA-approved cancer drug and quercetin is a plant flavonoid found in onions and capers.
Mayo Clinic trials have demonstrated that D+Q reduces senescent cell burden in human adipose tissue, lung, and kidney, and has shown improvements in physical function in patients with idiopathic pulmonary fibrosis and diabetic kidney disease ā both conditions with significant senescent cell involvement.
For healthy adults without specific senescence-driven conditions, the evidence is less established. Several trials are ongoing. The key insight from animal studies is that senolytic treatment does not need to be continuous ā a "pulsed" protocol (a few days of treatment every one to three months) appears sufficient because cleared cells take time to re-accumulate.
Fisetin ā a flavonoid found in strawberries ā has also shown senolytic properties in mouse models and is available as a supplement, though its bioavailability challenges limit enthusiasm.
Practical stance: Senolytics represent genuinely exciting biology with human proof-of-concept in specific disease populations. For healthy adult use, the risk-benefit calculation is less clear, particularly for dasatinib (a powerful drug with significant side effects at cancer doses). Quercetin and fisetin at supplement doses are low-risk approaches to partial senolytic activity while clinical evidence matures.
Metformin: The Quiet Contender
Metformin is the world's most widely prescribed diabetes drug and, incidentally, one of the most interesting longevity compounds. Epidemiological studies consistently show that diabetic patients taking metformin have lower all-cause mortality and lower cancer incidence than diabetic patients on other medications ā and in some analyses, lower mortality than matched non-diabetic controls not taking any diabetes drug.
The TAME trial (Targeting Aging with Metformin), the first clinical trial specifically designed to test a longevity intervention in healthy older adults, is expected to complete reporting in 2027. It is randomising 3,000 participants aged 65ā79 to metformin or placebo for six years, with a composite endpoint capturing age-related diseases and mortality.
Metformin's mechanisms include AMPK activation, mild mitochondrial complex I inhibition, gut microbiome modulation, and anti-inflammatory effects. There is, however, an important caveat for physically active individuals: several studies suggest metformin blunts the adaptive benefits of exercise training, particularly muscle hypertrophy and VO2 max gains. This interaction is dose-dependent and not fully characterised.
Practical stance: Metformin is the most evidence-adjacent longevity drug, with compelling epidemiology and clear mechanisms. The exercise interaction warrants caution for athletes or highly active individuals. It remains a prescription drug and should be approached accordingly.
GlyNAC: Glutathione Restoration
Glutathione ā the body's master antioxidant ā declines significantly with age, and this decline is associated with oxidative stress, mitochondrial dysfunction, and impaired cellular defence. GlyNAC (glycine + N-acetylcysteine) provides the two limiting precursors for glutathione synthesis.
A series of trials from Baylor College of Medicine led by Dr. Rajagopal Sekhar has shown that GlyNAC supplementation in older adults restores glutathione levels to youthful concentrations and produces improvements across multiple hallmarks of aging: mitochondrial function, oxidative stress markers, insulin resistance, physical strength, cognition, and inflammation. The most recent trial in 2025 showed meaningful cognitive improvements over 24 weeks.
The safety profile is excellent ā both glycine and NAC are well-characterised and inexpensive. The evidence base is still from a single research group and needs independent replication, but the mechanistic rationale is robust.
Practical stance: Among the most accessible and cost-effective additions to a longevity stack. Dosing from trials: glycine 1.77 mg/kg/day and NAC 1.33 mg/kg/day ā roughly 9 g glycine and 6 g NAC daily for a 70 kg adult.
Taurine: The Surprising New Contender
A high-profile 2023 paper in Science by Columbia University researchers generated significant excitement by demonstrating that taurine ā an amino acid abundant in meat and fish ā declines with age in humans, mice, and monkeys, and that supplementation extended median lifespan by 10ā12% in middle-aged mice with improvements across multiple healthspan metrics.
Human evidence for longevity specifically is limited, but taurine is widely used in sports nutrition and energy drinks, has an excellent safety profile, and appears to support mitochondrial function and reduce inflammation. Several ongoing trials are investigating its effects in older adults.
Practical stance: Low risk, plausible mechanism, interesting animal data, limited but not zero human evidence. A reasonable addition at 1ā3 g/day.
Omega-3 Fatty Acids and Vitamin D3+K2
These warrant mention not because they are novel but because the evidence for genuine longevity effects ā not just disease risk reduction ā has strengthened considerably.
The VITAL trial (20,000 participants, five years) showed that omega-3 supplementation at 1 g/day produced a significant reduction in cancer mortality and cardiovascular events in primary prevention, effects that strengthened with longer follow-up. More recent analysis suggests a dose-response relationship favouring higher intakes (2ā4 g/day) for cardiovascular outcomes.
Vitamin D3 combined with K2 (to direct calcium appropriately) has a large epidemiological literature associating sufficiency with reduced all-cause mortality, improved immune function, and lower cancer risk. The distinction between correcting deficiency (clearly beneficial) and supplementing beyond sufficiency (less clear) remains important.
The Non-Negotiable Foundations
No supplement stack compensates for fundamental lifestyle dysfunction. The evidence hierarchy puts these interventions above any compound:
Exercise remains the most powerful longevity tool available. The combination of zone 2 cardiovascular training (four to five hours per week at conversational pace, building mitochondrial density) and resistance training (preserving muscle mass, which is independently predictive of survival) is mechanistically sound and backed by decades of robust human data. VO2 max is one of the strongest predictors of all-cause mortality ā improving it adds more quality-adjusted life years than virtually any pharmaceutical intervention studied.
Sleep (covered separately in depth) ā the glymphatic system that clears the brain's metabolic waste, including amyloid, functions primarily during deep sleep. Consistently sleeping seven to nine hours is not optional in any serious longevity framework.
Caloric restriction and fasting protocols ā the most replicated longevity intervention in animal models. Human translation is complex, but time-restricted eating (16:8 protocols) and periodic prolonged fasting (24ā72 hours quarterly) show beneficial effects on autophagy, insulin sensitivity, and inflammatory markers without the unsustainable degree of caloric restriction used in animal studies.
Stress and social connection ā the Whitehall studies and the Harvard Study of Adult Development (now spanning 85 years) remain sobering reminders that psychosocial factors ā quality relationships, perceived control, purpose ā predict lifespan as strongly as most biomedical factors we focus on.
Biomarkers Worth Tracking
A data-driven approach to longevity requires knowing where you start and measuring progress. The most informative biomarkers available in 2026:
Epigenetic clocks ā DNA methylation patterns that correlate strongly with biological age. Tests like the Dunedin PACE clock and Horvath clock provide a biological age estimate that responds measurably to lifestyle interventions and some supplements. Available commercially for $200ā$400 per test; most useful when repeated at 6ā12 month intervals.
VO2 max ā the gold standard cardiovascular fitness measure, strongly predictive of mortality. Ideal testing requires a metabolic cart but is available at many sports medicine facilities; proxy estimates from heart rate recovery are adequate for tracking trends.
HOMA-IR and fasting insulin ā sensitive early markers of metabolic dysfunction, far more predictive than fasting glucose alone.
Apolipoprotein B (ApoB) ā a more reliable cardiovascular risk marker than LDL-C; represents the particle number of atherogenic lipoproteins.
hsCRP ā high-sensitivity C-reactive protein, a marker of systemic inflammation and a component of the biological aging process.
IGF-1 ā insulin-like growth factor 1, a marker of anabolic signalling that ideally sits in a moderate range ā neither too high (accelerating aging) nor too low (impairing tissue maintenance).
Grip strength and gait speed ā surprisingly predictive of mortality, especially in adults over 60. Simple to measure, reflecting underlying muscle and neuromuscular health.
Building Your Actual Stack
Given everything above, a reasonable evidence-based approach for a healthy adult in their 30sā50s might look like this:
High confidence (strong mechanisms, meaningful human evidence):
- NMN or NR: 500 mg/day
- Omega-3 EPA+DHA: 2ā3 g/day (triglyceride form for absorption)
- Vitamin D3: 2,000ā4,000 IU/day with K2 (100ā200 mcg MK-7)
- GlyNAC: ~9 g glycine + ~6 g NAC daily
- Magnesium glycinate: 400 mg/day (widely deficient; affects hundreds of enzymatic processes)
Moderate confidence (good mechanistic rationale, early-stage human evidence):
- Taurine: 1ā3 g/day
- Quercetin: 500ā1,000 mg/day (with periodic higher doses as a mild senolytic)
- Fisetin: 500 mg/day for a few days monthly
Medical supervision required (genuine promise, meaningful risks):
- Rapamycin: low-dose weekly protocol under physician oversight
- Metformin: prescription drug; consider trade-offs with exercise
Lifestyle non-negotiables (if these are not in place, supplements are rounding errors):
- 150+ minutes zone 2 cardio per week
- 2ā3 resistance training sessions per week
- 7ā9 hours sleep per night
- Time-restricted eating 14ā16 hours fast daily
The Honest Assessment
Longevity science in 2026 is simultaneously more rigorous and more uncertain than the popular discourse suggests. The biology is compelling; the human clinical evidence for most interventions remains incomplete.
The most intellectually honest position holds several things simultaneously: that aging is a biological process with identifiable targets; that some interventions show enough promise to be worth considering at low risk; that the lifestyle fundamentals are far better proven than any supplement; and that certainty is not yet available for most of the exciting compounds under investigation.
The TAME and PEARL trial results expected in 2027 will be landmark moments ā the first large, rigorously designed randomised controlled trials targeting aging itself rather than specific age-related diseases in humans. Those results will substantially update what we know.
Until then, the optimal approach combines the best-evidenced lifestyle practices, a thoughtful selection of low-risk supplements with plausible mechanisms, regular monitoring of meaningful biomarkers, and a healthy scepticism toward claims that outrun the evidence.
Living longer is increasingly a scientific aspiration rather than a fantasy. Living better in the years you have is available right now ā and the two goals, it turns out, overlap almost entirely.
This article is for informational and educational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before starting any supplement regimen or making changes to your health approach, particularly regarding prescription medications like rapamycin or metformin.